Allogene Therapeutics, INC

Allogene Therapeutics has named Dr. Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding Dr. David Chang.

Allogene Therapeutics terminates its exclusive license agreement with Overland Therapeutics and provides a corporate update with Q1 2026 financial results, highlighting progress in its cema-cel and ALLO-329 clinical trials.

Allogene Therapeutics has priced a public offering of 87.5 million shares of common stock at $2.00 per share to raise $175 million in gross proceeds.

Allogene Therapeutics announced a proposed underwritten public offering of its common stock, suspending sales under its existing at-the-market program.

Allogene Therapeutics announced interim futility analysis from its Phase 2 ALPHA3 trial showing significantly higher MRD negativity rates with cema-cel compared to observation in first-line LBCL.

Allogene Therapeutics announced its fourth quarter and full year 2025 financial results and provided key updates on its pivotal ALPHA3 and RESOLUTION clinical trials.

Allogene Therapeutics reports reduced net losses and significant clinical advancements for its CAR T programs, while managing a workforce reduction and ongoing capital needs.

Allogene Therapeutics reported a reduced net loss in Q2 2025, extended its cash runway into late 2027, and advanced key clinical programs while discontinuing a lymphodepletion agent due to a serious adverse event.

Allogene Therapeutics amends its strategic collaboration with Foresight Diagnostics and updates its non-employee director compensation policy, as detailed in its latest 10-Q filing.

Allogene Therapeutics reports a net loss of $66.3 million for Q3 2024, focusing on core programs and advancing clinical trials.

Allogene Therapeutics reports a net loss of $66.4 million for the second quarter of 2024, while focusing on key clinical programs and expanding its licensed territory.

Allogene Therapeutics reported a net loss of $65 million for Q1 2024, while focusing on key clinical programs and expanding its license for CD19 products to Europe and the UK.

Allogene Therapeutics reports a $190.9 million net loss in 2025, advancing its allogeneic CAR T pipeline with key clinical milestones expected in 2026 and 2027, while managing operational risks and capital needs.

Allogene Therapeutics prioritizes its LBCL, autoimmune disease, and RCC programs while reporting a $257.6 million net loss for the year ended December 31, 2024.

Allogene Therapeutics restated prior financials due to an accounting error and is now focusing on a pivotal Phase 2 trial for its CAR T-cell therapy in first-line lymphoma treatment.

Allogene Therapeutics has amended its annual report to restate financial statements due to an SEC comment regarding accounting for a joint venture, impacting revenue and expense recognition.

Allogene Therapeutics, Inc. reports that President and CEO Zachary Roberts acquired a significant number of Restricted Stock Units and Stock Options.

Allogene Therapeutics SVP of Finance Annie Yoshiyama sold shares to cover tax withholding obligations upon vesting of restricted stock units.

Allogene Therapeutics reports a "sell to cover" transaction by SVP, Chief Technical Officer Benjamin Machinas to satisfy tax withholding obligations upon vesting of restricted stock units.

Allogene Therapeutics' SVP and Chief Technical Officer, Benjamin Beneski, sold 4,835 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Allogene Therapeutics' President and CEO, David D. Chang, sold 47,763 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Allogene Therapeutics' SVP, Chief Technical Officer, Benjamin Beneski, sold 7,132 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Allogene Therapeutics announces its 2026 Annual Meeting, seeking shareholder approval to double authorized common stock to 800 million shares.

Allogene Therapeutics, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.

Allogene Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals for director elections, executive compensation advisory vote, and ratification of the independent accounting firm.

Allogene Therapeutics has filed a definitive proxy statement related to its upcoming shareholder meeting.

Allogene Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, executive compensation, and auditor ratification.

Pfizer Inc. reported a decrease in its beneficial ownership of Allogene Therapeutics, Inc. common stock to 9.0%, solely due to an increase in Allogene's outstanding shares.

Citadel Advisors and Kenneth Griffin have filed a Schedule 13G reporting a combined beneficial ownership of 2.8% in Allogene Therapeutics, Inc.

Dr. Arie Belldegrun and affiliated entities have filed a Schedule 13G reporting a 5.4% beneficial ownership stake in Allogene Therapeutics, Inc.

Dr. David D. Chang and associated family trusts report a 4.9% beneficial ownership stake in Allogene Therapeutics, Inc.

Frazier Life Sciences entities filed a Schedule 13G reporting a combined beneficial ownership of approximately 4.7% in Allogene Therapeutics, Inc.

Dr. David D. Chang and affiliated trusts report a combined beneficial ownership of 5.2% in Allogene Therapeutics, Inc. common stock.

Dr. Arie Belldegrun and affiliated entities, including Vida Ventures, have filed an amended Schedule 13G disclosing their beneficial ownership of 5.6% of Allogene Therapeutics, Inc. common stock.